BioNexus Gene Lab (BGLC) EBITDA (2018 - 2026)

BioNexus Gene Lab has disclosed EBITDA across 9 years of filings, most recently posting -$521675.0 for Q1 2026.

• EBITDA for Q1 2026 came in at -$521675.0, up 5.35% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.5 million (down 47.11% YoY), and the FY2025 annual result was -$2.6 million, down 72.78% from the prior year.
• EBITDA came in at -$521675.0 for Q1 2026 at BioNexus Gene Lab, up from -$1.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $431764.0 in Q4 2023 to a low of -$2.6 million in Q3 2023.
• The 5-year median for EBITDA is -$397993.0 (2022), against an average of -$477065.9.
• Across the five-year window, EBITDA slumped 2294.97% in 2022 and surged 133.98% in 2024, its largest moves.
• BioNexus Gene Lab's EBITDA stood at $241359.0 in 2022, then soared by 78.89% to $431764.0 in 2023, then plunged by 346.75% to -$1.1 million in 2024, then grew by 1.98% to -$1.0 million in 2025, then surged by 50.05% to -$521675.0 in 2026.
• The last three EBITDA figures came in at -$521675.0 (Q1 2026), -$1.0 million (Q4 2025), and -$705775.0 (Q3 2025), per Business Quant data.